CN111344004A - 一种调控glp-1/glp-1r 的方法和药物 - Google Patents

一种调控glp-1/glp-1r 的方法和药物 Download PDF

Info

Publication number
CN111344004A
CN111344004A CN201880046475.0A CN201880046475A CN111344004A CN 111344004 A CN111344004 A CN 111344004A CN 201880046475 A CN201880046475 A CN 201880046475A CN 111344004 A CN111344004 A CN 111344004A
Authority
CN
China
Prior art keywords
plasminogen
glp
mice
group
control group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880046475.0A
Other languages
English (en)
Inventor
李季男
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Talengen Institute of Life Sciences Co Ltd
Original Assignee
Talengen Institute of Life Sciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Talengen Institute of Life Sciences Co Ltd filed Critical Talengen Institute of Life Sciences Co Ltd
Publication of CN111344004A publication Critical patent/CN111344004A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

本发明公开了纤溶酶原调控GLP‑1/GLP‑1R及治疗GLP‑1/GLP‑1R相关病症的用途。

Description

PCT国内申请，说明书已公开。

Claims (30)

  1. PCT国内申请，权利要求书已公开。
CN201880046475.0A 2017-06-19 2018-06-19 一种调控glp-1/glp-1r 的方法和药物 Pending CN111344004A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2017/089067 2017-06-19
CN2017089067 2017-06-19
PCT/CN2018/091838 WO2018233604A1 (zh) 2017-06-19 2018-06-19 一种调控glp-1/glp-1r的方法和药物

Publications (1)

Publication Number Publication Date
CN111344004A true CN111344004A (zh) 2020-06-26

Family

ID=64737520

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880046475.0A Pending CN111344004A (zh) 2017-06-19 2018-06-19 一种调控glp-1/glp-1r 的方法和药物

Country Status (7)

Country Link
US (1) US11938172B2 (zh)
EP (1) EP3643321A4 (zh)
JP (2) JP7335609B2 (zh)
CN (1) CN111344004A (zh)
CA (1) CA3067890A1 (zh)
TW (1) TWI714862B (zh)
WO (1) WO2018233604A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201829448A (zh) 2016-12-15 2018-08-16 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途
CA3046666A1 (en) 2016-12-15 2018-06-21 Talengen International Limited Method for preventing and treating tissue and organ fibrosis
TW202143999A (zh) * 2020-03-24 2021-12-01 大陸商深圳瑞健生命科學研究院有限公司 一種促進錯誤摺疊蛋白及其聚集物降解的方法和藥物
TW202144001A (zh) * 2020-03-24 2021-12-01 大陸商深圳瑞健生命科學研究院有限公司 一種治療阿茲海默症的方法和藥物
WO2021190563A1 (zh) * 2020-03-24 2021-09-30 泰伦基国际有限公司 一种治疗亨廷顿病的方法和药物
CN115697386A (zh) * 2020-03-24 2023-02-03 泰伦基国际有限公司 一种治疗帕金森病的方法和药物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304383A (en) * 1990-10-11 1994-04-19 Immuno Aktiengesellschaft Pharmaceutical preparation based on Lys-plasminogen
CN101914150A (zh) * 2009-03-12 2010-12-15 刘建宁 一种多肽及其在制药中的应用
US20130303436A1 (en) * 2012-12-06 2013-11-14 Stealth Peptides Internatioanl, Inc. Peptide therapeutics and methods for using same
CN105849122A (zh) * 2013-11-06 2016-08-10 西兰制药公司 Gip-glp-1双重激动剂化合物及方法
WO2017077380A1 (en) * 2015-11-03 2017-05-11 Prometic Biotherapeutics, Inc. Plasminogen replacement therapy for plasminogen-deficiency

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4645668A (en) 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
GB8721951D0 (en) 1987-09-18 1987-10-28 Thrombosis Research Trust Organic compounds
DE4411143C2 (de) * 1994-03-30 1996-08-01 Immuno Ag Thrombosemittel
WO1997041824A2 (en) 1996-05-03 1997-11-13 Abbott Laboratories Antiangiogenic peptides derived from plasminogen
WO1999000420A1 (en) 1997-06-26 1999-01-07 Karolinska Innovations Ab Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo
AU5571799A (en) 1998-08-20 2000-03-14 University Of Vermont And State Agricultural College, The Angiogenesis inhibitors and uses thereof
US7763580B2 (en) 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
AU3173301A (en) * 2000-02-11 2001-08-20 European Molecular Biology Laboratory Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
AU2002239414A1 (en) 2000-11-02 2002-05-27 Bristol-Myers Squibb Company Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors
MXPA00011713A (es) 2000-11-28 2002-05-31 Tgt Lab S A De C V Vectores recombinantes virales y no virales conteniendo el gen humano del activador de plasminogeno derivado de urocinasa y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar, pancreatica, cardiaca y cicatrices hipe
US7067492B2 (en) 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
US20050124036A1 (en) 2002-02-06 2005-06-09 Rudy Susilo Method for producing recombinant proteins in micro-organisms
CA2475277A1 (en) 2002-02-06 2003-08-14 Trommsdorff Gmbh & Co. Kg Arzneimittel Method for producing recombinant proteins in micro-organisms
JP2006507297A (ja) 2002-05-13 2006-03-02 チルドレンズ・ホスピタル・ロサンジェルス ケロイドおよび他の皮膚または内部創傷または病変における異常瘢痕形成の処置および予防
WO2004052853A2 (en) 2002-12-10 2004-06-24 Wyeth Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
US20050250694A1 (en) 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
BRPI0514549A (pt) 2004-08-23 2008-06-17 Wyeth Corp ácidos de pirrol-naftila como inibidores de pai-1
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
WO2008026999A2 (en) 2006-08-28 2008-03-06 Omnio Healer Ab Candidates against infection
US20100080773A1 (en) 2008-09-26 2010-04-01 Sdg, Inc. Orally Bioavailable Lipid-Based Constructs
AU2008331545B2 (en) 2007-11-29 2014-01-16 Grifols Therapeutics Inc. Recombinantly modified plasmin
KR20120050442A (ko) 2009-07-10 2012-05-18 쓰롬보제닉스 엔.브이. 플라스미노겐 및 플라스민의 변이체
CN101628113B (zh) 2009-08-18 2012-01-04 南京农业大学 蚯蚓纤溶酶抗肝纤维化的应用
CA2779905A1 (en) 2009-11-07 2011-05-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5188523B2 (ja) * 2010-03-03 2013-04-24 雪印メグミルク株式会社 骨形成促進及び骨吸収抑制剤
WO2011139974A2 (en) 2010-05-03 2011-11-10 Abbott Laboratories Anti-pai-1 antibodies and methods of use thereof
CN102121023B (zh) 2010-12-22 2012-07-04 中山大学 突变型人纤溶酶原kringle5及其制备方法及应用
CA2823491A1 (en) 2011-01-05 2012-07-12 Thrombogenics Nv Plasminogen and plasmin variants
CN102154253A (zh) 2011-01-06 2011-08-17 郑州大学 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途
US8659929B2 (en) 2011-06-30 2014-02-25 Crossbar, Inc. Amorphous silicon RRAM with non-linear device and operation
US9655973B2 (en) 2012-03-09 2017-05-23 Vascular Biosciences Orally active, cell-penetrating homing peptide and methods of using same
KR101467109B1 (ko) 2013-07-10 2014-12-01 영남대학교 산학협력단 Ｂｉｘ02189 화합물을 유효성분으로 포함하는 폐섬유증 예방 또는 치료용 조성물
TW201734054A (zh) 2013-08-13 2017-10-01 賽諾菲公司 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途
CN104371019B (zh) 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
EA033403B1 (ru) 2013-08-13 2019-10-31 Sanofi Sa Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
WO2015026494A2 (en) 2013-08-20 2015-02-26 Trustees Of Dartmouth College Methods for treating tissue fibrosis
EP3109320B1 (en) 2014-02-21 2019-03-27 Astellas Pharma Inc. New anti-human pai-1 antibody
RU2711989C2 (ru) 2014-12-19 2020-01-23 Прометик Байо Терапьютикс, Инк. Фармацевтическая композиция, содержащая плазминоген, и ее применение
EP3395354B1 (en) 2015-12-18 2024-05-22 Talengen International Limited Plasminogen for use in treating diabetic nephropathy
JP2019500422A (ja) 2015-12-18 2019-01-10 タレンゲン インターナショナル リミティッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 急性及び慢性血栓を予防または治療することに用いる方法
US11400142B2 (en) 2015-12-18 2022-08-02 Talengen International Limited Treatment of diabetic nerve injury comprising administering plasminogen
DK3391902T3 (da) * 2015-12-18 2023-11-20 Talengen Int Ltd Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
WO2017101873A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防或治疗放射性和化学性损伤的方法
CN106890324A (zh) 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种预防和治疗糖尿病肾病的方法
CN106890318A (zh) 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种预防和治疗糖尿病性心脏病的新方法
CN106890320A (zh) 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种用于预防或治疗急性及慢性血栓的方法
CA3047171A1 (en) 2016-12-15 2018-06-21 Talengen International Limited Method for preventing and treating pathological renal tissue injury
US11389515B2 (en) 2016-12-15 2022-07-19 Talengen International Limited Method for mitigating heart disease
TW201829448A (zh) 2016-12-15 2018-08-16 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途
CA3046666A1 (en) 2016-12-15 2018-06-21 Talengen International Limited Method for preventing and treating tissue and organ fibrosis
EP3556381A4 (en) * 2016-12-15 2020-09-23 Talengen International Limited MEDICINAL PRODUCT FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS AND ITS USES
EP3556384B1 (en) 2016-12-15 2024-04-10 Talengen International Limited Plasminogen for use in treating diabetes
TWI684459B (zh) * 2016-12-15 2020-02-11 大陸商深圳瑞健生命科學研究院有限公司 一種治療動脈粥樣硬化及其併發症的方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304383A (en) * 1990-10-11 1994-04-19 Immuno Aktiengesellschaft Pharmaceutical preparation based on Lys-plasminogen
CN101914150A (zh) * 2009-03-12 2010-12-15 刘建宁 一种多肽及其在制药中的应用
US20130303436A1 (en) * 2012-12-06 2013-11-14 Stealth Peptides Internatioanl, Inc. Peptide therapeutics and methods for using same
CN105849122A (zh) * 2013-11-06 2016-08-10 西兰制药公司 Gip-glp-1双重激动剂化合物及方法
WO2017077380A1 (en) * 2015-11-03 2017-05-11 Prometic Biotherapeutics, Inc. Plasminogen replacement therapy for plasminogen-deficiency

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JENNIFERA. HUNT等: "Simplified recombinant plasmin:Production and functional comparison of a novel thrombolytic molecule with plasma –derived plasmin", 《THROMBOSIS AND HAEMOSTASIS》 *
JENNIFERA. HUNT等: "Simplified recombinant plasmin:Production and functional comparison of a novel thrombolytic molecule with plasma –derived plasmin", 《THROMBOSIS AND HAEMOSTASIS》, vol. 100, no. 3, 14 August 2008 (2008-08-14), pages 413 - 419, XP009113156 *
无: "NCBI Reference Sequence: 1BUI_A", 《GENBANK》, 31 October 2012 (2012-10-31) *
无: "Sequence: NP_000292.1", 《GENBANK》 *
无: "Sequence: NP_000292.1", 《GENBANK》, 23 April 2016 (2016-04-23) *
罗明泉主编: "《内分泌及代谢系统健康330问》", 人民军医出版社, pages: 246 - 247 *

Also Published As

Publication number Publication date
JP2020524161A (ja) 2020-08-13
WO2018233604A1 (zh) 2018-12-27
TW201906627A (zh) 2019-02-16
JP7335609B2 (ja) 2023-08-30
TWI714862B (zh) 2021-01-01
JP2023156429A (ja) 2023-10-24
EP3643321A1 (en) 2020-04-29
US20200206324A1 (en) 2020-07-02
US11938172B2 (en) 2024-03-26
EP3643321A4 (en) 2021-05-05
CA3067890A1 (en) 2018-12-27

Similar Documents

Publication Publication Date Title
CN111344004A (zh) 一种调控glp-1/glp-1r 的方法和药物
JP7117012B2 (ja) 糖尿病網膜症を予防または治療するための方法
TWI642442B (zh) 纖溶酶原在製備降低胰高血糖素分泌的藥物上的用途
TW201722465A (zh) 一種預防或治療糖尿病性神經損傷及其相關病症的方法
CN109125715A (zh) 一种调控glp-1/glp-1r的方法和药物
TW201829448A (zh) 纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途
WO2021143906A1 (zh) 一种治疗神经损伤及其相关病症的方法
TWI787767B (zh) 一種治療亨廷頓病的方法和藥物
WO2021190561A1 (zh) 一种治疗帕金森病的方法和药物
CN111905103A (zh) 一种治疗肌萎缩侧索硬化的方法和药物
JP7455457B2 (ja) 筋萎縮性側索硬化症を治療するための方法と薬剤
TW202408566A (zh) 一種治療神經損傷及其相關病症的方法
TW202228766A (zh) 一種治療神經損傷及其相關病症的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination